CANaspire Clinical Trial Update: Letter To The Canavan Community
Aspa Therapeutics, a BridgeBio company, has released a November 17, 2026 update for the Canavan disease community regarding CANaspire, its clinical trial evaluating the investigational gene therapy BBP-812. The update addresses a manufacturing issue that has delayed the production of new study material, with dosing currently anticipated to resume in mid-2027. Aspa Therapeutics also shares […]
CANaspire Clinical Trial Update: Letter To The Canavan Community Read More »
